Navigation Links
Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Date:11/20/2007

ST. JOSEPH, Mich., Nov. 20 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug in their prestige master program for drug innovation. MetaDrug is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL's Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases.

"Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug is state-of-the-art, but still very accessible to the novice user," said Dr Ed Moret. "We really like the support and training they have offered to our students."

"GeneGo is very serious about including MetaDrug in academic environments especially for teaching," said Julie Bryant, Vice President of Business Development for GeneGo. "Academia pushes the limits of MetaDrug which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. University of Leicester scientists discover technique to help friendly bacteria
7. MichBio Announces Student Career Day at Michigan State University
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
11. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, ... Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma ... Cancer Institute. The event is free and open to the public, but registration ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):